Targeting PSMA in Prostate Cancer Treatment

home / expert-perspective-tumor-board / targeting-psma-in-prostate-cancer-treatment

Experts review prostate cancer clinical cases and discuss approaches to treating patients with PSMA targeted therapies.

EP. 1: Initial Risk Stratification of Localized Prostate Cancer

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

June 10th 2022

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

Watch

EP. 2: Defining PSMA-PET Scans for Prostate Cancer

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

July 1st 2022

Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.

Watch

EP. 3: Case 1: Metastatic Castrate-Resistant Prostate Cancer

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

July 1st 2022

Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Watch

EP. 4: PSMA-Positive mCRPC and the VISION Trial

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

July 8th 2022

Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.

Watch

EP. 5: Lutetium-PSMA-617 for Prostate Cancer Treatment

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

July 8th 2022

A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.

Watch

EP. 6: Radium-223 and the ALSYMPCA Trial

Alicia K. Morgans, MD, MPH;Tanya Dorff, MD;Phillip J. Koo, MD;Ulka Vaishampayan, MD

July 18th 2022

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

Watch

EP. 7: Case 2: Metastatic Hormone-Sensitive Prostate Cancer